25 March 2019

PDMR Dealing

LONDON, March 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 22, 2019, Mr. Piers Morgan, CFO of the Company, purchased 20,132 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 64 pence per Ordinary Share and a total purchase price of £12,884.48  Following the acquisition, Mr. Morgan will have an interest in the Company of 113,207 Ordinary Shares, representing 0.11% of the Company’s issued share capital.

The purchase by Mr. Morgan brings the total purchases made by him this month to £32,884.46 and follows the purchases made by the Company’s Chairman, Dr. David Ebsworth, earlier this month totaling approximately £50,000.00.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1 Details of the person discharging managerial responsibilities/person closely associated

a)
 

Name
 

Piers Morgan
 
2 Reason for the notification

a)
 
Position/status Chief Financial Officer

b)
 
Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)
 
Name Verona Pharma plc

b)
 
LEI 213800EVI6O6J3TIAL06

 

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code
 
Ordinary Shares of 5 pence each

GB00BYW2KH80

b)
 

Nature of the transaction
 
Piers Morgan purchased 20,132 Ordinary Shares

c)

Price(s) and volume(s)

 
Price(s) Volume(s)
64 pence per Ordinary Share 20,132 Ordinary Shares

d)

Aggregated information

-  Aggregated volume

-  Price

N/A

e)
 
Date of the transaction 22 March 2019

f)
 
Place of the transaction London Stock Exchange, AIM

 

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
info@veronapharma.com
   
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison  

Verona.jpg

 

Source: Verona Pharma plc


For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200

 

 

Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 950 9144
verona@optimumcomms.com

Argot Partners (Investor enquiries)
Stephanie Marks
Tel. +1 646 644 9590
verona@argotpartners.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us